Innovation in Colorectal Cancer Therapeutic Market with the development of New Adhesive Pack That Increase Its Treatment's Efficacy

Colorectal cancer is the third most prevalent disease in the U.S., with approximately one in twenty people contacting it in their lifetimes. In Europe, as well, it is known to be the second-most common type of cancer. Surgery is considered to be the most common treatment against this disease; however, it sometimes results in incomplete removal of the tumor. At times, cancer cells can be left behind, elevating the chance of tumor recurring or increasing the risk of metastasis. In many cases, patients remain cancer-free for years, but it recurs after a while in 50% of the cases. Traditional therapies that prevent such instances from happening are not able to actively differentiate between the healthy and cancerous cells, leading to disastrous side effects.

Recently, an adhesive pack has been developed with the ability to stick at the tumor site, before or after surgery. This is, so it can deliver a triple-combination of drug, photo, and gene therapy. This is a breakthrough innovation for Colorectal Cancer Therapeutic Market as releasing this triple combination therapy specifically at the tumor site would increase the treatment's efficacy.

The newly developed triple-therapy hydrogel patch might be particularly effective in contrast with other currently available therapies. This is because it treats the tumor itself and removes all cells left at the site after surgery. Thus, reducing the chances of cancer recurring or metastasizing in the future.

The patch was made through a complex process and had an intricate working system as well. Firstly, it contains gold nanorods, and they heat up once near-infrared radiation is applied to the local area. The nanorods are responsible for thermally ablate or destroy the tumor. They are also equipped with a chemotherapy drug that gets released and targets the tumor and surrounding cells when nanorods are heated. At last, gold nanospheres that remain unheated work as a transporter to deliver RNA or gene therapy to the site so that oncogene (Genes that can convert healthy cells into tumor cells) present in colorectal cancer can be silenced.

The researchers imagine that a clinician would be able to remove the tumor and then apply the patch to the colon's inner surface. This will ensure that no cells would remain on-site that can cause cancer to recur. Over time, degradation of the patch would release various therapies. Moreover, the patch can also serve as a neoadjuvant, a therapy that can shrink tumors before resection.

The new technology is an excellent and unique combination of three concurrent modalities of treatment. The most intriguing aspect of it is that it serves the treatment locally, which means that multimodal therapy might be more effective than systematic therapy in specific clinical situations.

Reference: https://www.valuemarketresearch.com/report/colorectal-cancer-therapeutic-market